These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30976833)

  • 1. Adalimumab in the treatment of pediatric Behçet's disease: case-based review.
    Poddighe D; Mukusheva Z; Dauyey K; Assylbekova M
    Rheumatol Int; 2019 Jun; 39(6):1107-1112. PubMed ID: 30976833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
    Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
    BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with Biologic Drugs in Pediatric Behçet's Disease: A Comprehensive Analysis of the Published Data.
    Batu ED; Sener S; Cam V; Aktay Ayaz N; Ozen S
    BioDrugs; 2023 Nov; 37(6):813-828. PubMed ID: 37382804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radial artery occlusion, a rare presentation of Behçet's disease.
    Gera C; Jose W; Malhotra N; Malhotra V; Dhanoa J
    J Assoc Physicians India; 2008 Aug; 56():643-4. PubMed ID: 19051714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness of adalimumab as an add-on therapy in two cases with leg ulcers in Behçet's disease resistant to conventional immunosuppressive therapy alone and a review of the literature.
    Kaban N; Harman H
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):205-209. PubMed ID: 37534898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked improvement in gastric involvement in Behçet's disease with adalimumab treatment.
    Sonoda A; Ogawa R; Mizukami K; Fukuda K; Shuto M; Okamoto K; Matsunari O; Okimoto T; Murakami K
    Turk J Gastroenterol; 2017 Sep; 28(5):405-407. PubMed ID: 28797990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal Behçet's disease with pyoderma gangrenosum successfully treated with the combination therapy of adalimumab and glucocorticoids.
    Kashiwado Y; Uchino A; Ota T; Nagano S
    Mod Rheumatol; 2018 Sep; 28(5):901-905. PubMed ID: 27142127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report.
    Marsili M; Marzetti V; Lucantoni M; Lapergola G; Gattorno M; Chiarelli F; Breda L
    Ital J Pediatr; 2016 Sep; 42(1):81. PubMed ID: 27600159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
    Tanida S; Inoue N; Kobayashi K; Naganuma M; Hirai F; Iizuka B; Watanabe K; Mitsuyama K; Inoue T; Ishigatsubo Y; Suzuki Y; Nagahori M; Motoya S; Nakamura S; Arora V; Robinson AM; Thakkar RB; Hibi T
    Clin Gastroenterol Hepatol; 2015 May; 13(5):940-8.e3. PubMed ID: 25245624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of adalimumab for older Behçet's disease complicated with pulmonary artery thrombosis: A case report.
    Yoshida S; Kimura Y
    Int J Rheum Dis; 2020 Jun; 23(6):837-839. PubMed ID: 32406191
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of severe complications in Behçet's disease with TNF inhibitors.
    Desbois AC; Vallet H; Domont F; Comarmond C; Cacoub P; Saadoun D
    Expert Opin Biol Ther; 2017 Jul; 17(7):853-859. PubMed ID: 28503960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet's disease.
    Kim HJ; Kim KT; Lee SG; Kim Y
    Z Rheumatol; 2020 Sep; 79(7):702-706. PubMed ID: 32494950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behçet's disease: New insights into pathophysiology, clinical features and treatment options.
    Greco A; De Virgilio A; Ralli M; Ciofalo A; Mancini P; Attanasio G; de Vincentiis M; Lambiase A
    Autoimmun Rev; 2018 Jun; 17(6):567-575. PubMed ID: 29631062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behçet's disease without formation of antidrug antibodies.
    Verboom DM; van der Houwen TB; Kappen JH; van Daele PLA; Dik WA; Schreurs MWJ; van Hagen PM; van Laar JAM
    Clin Exp Rheumatol; 2019; 37 Suppl 121(6):43-47. PubMed ID: 30873952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early administration of adalimumab for paediatric uveitis due to Behçet's disease.
    Hiyama T; Harada Y; Doi T; Kiuchi Y
    Pediatr Rheumatol Online J; 2019 Jun; 17(1):29. PubMed ID: 31182107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic therapy for Behçet's uveitis: a systematic review.
    Uke P; Gorodkin R; Beare N
    Br J Ophthalmol; 2020 Aug; 104(8):1045-1051. PubMed ID: 31676596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Colchicine in Different Clinical Phenotypes of Behcet Disease.
    Wang Z; Zu X; Xiong S; Mao R; Qiu Y; Chen B; Zeng Z; Chen M; He Y
    Clin Ther; 2023 Feb; 45(2):162-176. PubMed ID: 36732153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of adalimumab in Behçet's disease. Description of 6 cases].
    Calvo Catalá J; Campos Fernández C; Rueda Cid A; González-Cruz Cervellera MI; Baixauli Rubio A; Pastor Cubillo MD
    Reumatol Clin; 2011; 7(4):258-61. PubMed ID: 21794828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.